A preclinical study by Baun et al. evaluated the theranostic pair [55/58mCo]Co-DOTA-PSMA-617 for PET imaging and Auger therapy of prostate cancer using PC3-PIP (PSMA+), LNCaP (PSMA+), and PC3-flu (PSMA-) cell lines. This evidence concerns the gene FOLH1 and prostate cancer.